PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Milind Desai, MD, MBA - New Evidence on Cardiac Myosin Inhibition in Hypertrophic Cardiomyopathy: Analysis From Washington, DC
Go online to PeerView.com/XXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What’s new in the treatment of hypertrophic cardiomyopathy (HCM)? Hear what was presented at the 70th Annual Scientific Session and Expo of the American College of Cardiology (ACC 2022) from Dr. Milind Desai, as he shares the latest evidence on novel therapies for HCM and considers how these findings can improve outcomes for patients in your clinical practice. Upon completion of this activity, participants should be better able to: Identify the mechanism of action of cardiac myosin inhibitors for the treatment of HCM, Describe the benefits and limitations of current management strategies for patients with obstructive and nonobstructive HCM, Apply the current body of evidence for cardiac myosin inhibitors to improve outcomes and enhance quality of life in patients with obstructive and nonobstructive HCM, including as an alternative to septal reduction therapy.